Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Rating of “Hold” by Brokerages

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have received a consensus recommendation of “Hold” from the twelve ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $13.1429.

JSPR has been the subject of several research analyst reports. TD Cowen downgraded Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Royal Bank Of Canada set a $3.00 price target on shares of Jasper Therapeutics and gave the company a “sector perform” rating in a research note on Friday, May 15th. UBS Group assumed coverage on shares of Jasper Therapeutics in a report on Monday, March 23rd. They issued a “neutral” rating for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Tuesday, April 21st.

Jasper Therapeutics Price Performance

Shares of Jasper Therapeutics stock opened at $0.43 on Friday. Jasper Therapeutics has a twelve month low of $0.32 and a twelve month high of $7.19. The business has a 50-day moving average price of $0.68 and a 200 day moving average price of $1.12. The firm has a market cap of $11.99 million, a PE ratio of -0.13 and a beta of 3.07.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.08. On average, sell-side analysts expect that Jasper Therapeutics will post -1.67 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Engineers Gate Manager LP purchased a new position in Jasper Therapeutics in the 4th quarter valued at about $26,000. Panagora Asset Management Inc. purchased a new stake in Jasper Therapeutics during the 4th quarter worth approximately $35,000. Acadian Asset Management LLC purchased a new stake in Jasper Therapeutics during the 1st quarter worth approximately $46,000. Voleon Capital Management LP acquired a new position in shares of Jasper Therapeutics during the third quarter valued at approximately $50,000. Finally, Jain Global LLC acquired a new position in shares of Jasper Therapeutics during the fourth quarter valued at approximately $79,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.